In an effort to better harness the research resources of Harvard University to fight cancer, Dana-Farber Cancer Institute has joined with Harvard Medical School, four of its other affiliated hospitals, and Harvard School of Public Health to create the Dana-Farber/Harvard Cancer Center (DF/HCC).
The institutions which also include Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Children's Hospital Boston, and Massachusetts General Hospital are working to more quickly answer questions about the cause of cancer, cancer prevention, and the effectiveness of potential therapies by creating opportunities and incentives for collaboration among basic, clinical, and population researchers.
DF/HCC's 800 researchers have access to 18 core facilities, many of which are large, highly instrumented labs that are generally too expensive for any one researcher, or often, any one institution, to initiate. A large series of collaborative programs are organized around research on specific diseases (such as breast, gynecologic, leukemia, lymphoma, and prostate cancer). Other programs are structured by research disciplines, such as biostatistics, cancer immunology, outcomes research, and experimental therapeutics.
Dana-Farber Cancer Institute's designation by the National Cancer Institute as comprehensive cancer center was expanded to include the entire DF/HCC in 2000.
44 Binney Street
Boston, MA 02115